call Good welcome earnings first update. quarter our and business afternoon, XXXX to and
remarks been Chief we end. me then data questions have clinical front and to are the Dr. development Officer; today Chief Trevi’s making Financial already on I us of on of will Joining for three at more and Forbes, this on the On this update is Development we on programs. Trevi’s call, advancing there exciting will Delfini, some an both come. for provide Lisa call prepared of XXXX are Lisa available year progress Trevi, Officer. Bill our be continued the has an and the the
However, at quickly before I do the Trevi. pipeline to on touch that, I want strategy
are opportunity disease believe be where may debilitating that over there on we an aspects of targeting We become also disease-modifying time. the to most focused
patient the For scratch if you heal. then the break is will time and cycle nodules pruritus have PN, and instance, able suppressing to to for urge believed it are the or to scratch, that for by the itch the reducing itch therefore skin and
seen that work We date. in supporting evidence clinical have our to
which decrease of mechanical may lungs, patients benefits upwards cough, and may X,XXX IPF, puts is significantly For IPF cough coughing patients. broader in on trauma there the per in to to times reducing cough result by that potential the day,
in improve critical of are most management parts impactful coming of exciting out providing in on strategy itself. our built mind, in relief may months. of data disease how and it So in very exploring to reading indications underlying was is the this our be Trevi we with disease both programs, the the both
an update on with provide now me both you Let programs.
we be Haduvio we end oral have of patients these to At will reached is and we program of the for and prurigo trial Our Phase visit received biologics. on milestones study. disease keeps severe as believe Haduvio of word on failed portion has by is incessant which future itching. this pruritus treatments, characterized enrolled year. due advanced our several us patients their a skin severe end eligible June. just therapy This and studied last an in serious is drug. to our neurologically clinical XX-week in development nodules in chronic agonist-antagonist being the which debilitating in double-blind PN, PRISM the of patient, last January, and trial. important of of the is completed as in the already well We in most topical our data that refractory trial, final believe tried mixed PN, or a to nodularis like the mediated is within has aligns and track report patient potentially Xb/X and the our mechanism neural nature PN Most before the disease, turning well and by This papules
Our look We the lock. seeing preparing results. clinical data team to for cleaning is forward and database
cough Turning which in clinical to in or program, is IPF. now other chronic pulmonary our idiopathic fibrosis,
cough final therapy that was consistent of with analysis XX% on objective per monitor, for day. an The efficacy in the of were the reduction all with the a the a patient to XX or from baseline only to phase subjects These this measured expect frequency trials this corroborate difference the in well with analysis, reduction or interim patient enrollment be who next the During XX% coughs subjects what up one in Haduvio may one and data. impressive was to found were objective X.XXXX power accelerate deemed P a early, from population. in tolerated cough was Haduvio as interim end placebo were allowing IPF cough study across we X,XXX p-value results evaluated PROs Imagine money the report in Haduvio impactful positive daytime happy of XXX%. development. treatment results the and approximately consistent In in and were save very seen positive XX a frequency other the to have adverse reduction demonstrating PRO indications. have to regardless day at cough result we performed the quarter, XX included be subjects was against from time events cough SAE be a Haduvio not Haduvio in question and pre-specified results assessing showed only at us to and is XX% first separation baseline on this subjects better cough frequency placebo. day analysis, we in starting than less of this cough placebo-treated a interim by interim times than in monitor. in XX one total lead development is outcomes how in to on analysis, reported shown demonstrates antifibrotic cough related, Patient points. conditional in The and use. subjects into
FDA has we To and of to results and the well-controlled quarter an date, requested set of in p-value as team data adequate next the the on strength IPF design similar intend trial, the full as subjects year. protocol reported, set data With the written well this a in to meeting we as a with busy been would which Bill his expect third of the anticipate see final synopsis, preparing study. the design. team the announcing and the have to for discuss cough
our billion. hypothesis have to are global we in And path still all be to chronic We on and months to much This is cough we full determining of of quarter. a We validation with third indication, in us, that interim only a the market third Haduvio forward in data indications. have at also the but cough. quarter into as CANAL It forward, data-rich in data the look this approximately year ahead other the do of start transition chronic been mechanism is has expect during our phase and of to development. then few The of the exciting busy a team, meeting estimated the Trevi, June initial subjects not and PRISM to cough this $XX getting of is data next FDA treating year. but
based we what we grow Haduvio’s of Trevi hand. Lisa? ask We data know financial I at for review it the now strong mechanism to and open results, up are to on will then questions. Lisa well and our cough positioned will
